Pyruvate Kinase M2-Responsive Release of Paclitaxel and Indoleamine 2,3-Dioxygenase Inhibitor for Immuno-Chemotherapy of Nonsmall Cell Lung Cancer.

• Tác giả: Xufeng Chen, Yan Ding, Hui Jiang, Jinyu Li, Kaiming Li, Xiaolin Li, Gaolin Liang, Ya Lin, Yawen Lu, Xianbao Sun, Haisi Wu, Huae Xu, Dan Yan, Xiaole Zhu
• Ngôn ngữ: eng
• Ký hiệu phân loại: 633.14 *Rye
• Thông tin xuất bản: Germany : Advanced science (Weinheim, Baden-Wurttemberg, Germany) , 2025
• Bộ sưu tập: NCBI
• ID: 160318

Tóm tắt

Paclitaxel (PTX) is a first-line chemotherapeutic drug for non-small cell lung cancer (NSCLC) but it can induce indoleamine 2,3-dioxygenase (IDO) activation, which severely lowers down its immuno-chemotherapeutic effect. To address this issue, a smart peptide hydrogelator Nap-Phe-Phe-Phe-Lys-Ser-Thr-Gly-Gly-Lys-Ala-Pro-Arg-OH (Nap-T), which co-assembles with PTX and an IDO inhibitor GDC0919 to form a hydrogel GP@Gel Nap-T, is rationally designed. Upon specific phosphorylation by pyruvate kinase M2 (PKM2), an overexpressed biomarker of NSCLC, Nap-T is gradually converted to Nap-Phe-Phe-Phe-Lys-Ser-Thr(H